A new paradigm shift driven by acid control
Highlights from the 2024 Annual Report: Market overview
Acid control in this context means that the pH of the esophagus is kept above 4. If the pH drops below 4, the healing process is disturbed, and if the pH remains low, it may be interrupted. The figure shows an overview of different pharmaceutical agents and their ability to provide acid control over 24 hours.
PPIs was introduced in the late 1980s and quickly became the standard treatment for various stages of GERD, creating globally recognized brands such as Nexium and Losec. The first generation of PCABs entered the market in 2015 and offered a significant increase in acid control, 63-85%.
Demand for PCABs is expected to increase as a result of a growing patient population and unmet need, as many patients do not recover despite high-dose treatment with PPIs.
Linaprazan glurate has a 24-hour acid control of 92-96%, implying that it has the potential to be the be the best in class PCAB.
